A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies
Sponsors and collaborators
Michael Sosnowski 973-605-8200 ext 144 [email protected]
William A Wegener, MD, PhD Immunomedics, Inc.
Next post in Pancreatic Cancer Clinical Trials
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
Want to read more?
Please login or register first to view this content.